NATIONAL BREAST CANCER FOUNDATION (NBCF) OUTLINES PINK HORIZON RESEARCH STRATEGY AT BREAST CANCER FORUM Breast Cancer Awareness Month demonstrates integral role of NBCF in research and clinical support
Filmed in Brisbane, Queensland | November 2024
Associate Professor Cleola Anderiesz, Chief Executive Officer of the National Breast Cancer Foundation, leads an organisation dedicated to funding world-class breast cancer research in Australia. The Foundation has a bold vision of achieving zero deaths from breast cancer.
Every October, during Breast Cancer Awareness Month, the foundation uses this time to raise awareness about breast cancer and its impact in Australia. It also emphasises the critical need for funding breast cancer research to improve outcomes.
The National Breast Cancer Foundation collaborates with researchers, providing essential funding while also engaging them, clinicians, and consumers to establish research priorities.
Australian Health Journal met with Assoc Prof Anderiesz to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.
Recently, Assoc Professor Anderiesz presented at the Public Breast Cancer Research Forum hosted by The University of Queensland and the Translational Research Institute, where she highlighted the accomplishments of the National Breast Cancer Foundation over the past 30 years. During this time, the Foundation has invested over $200 million into more than 600 research projects across Australia, supporting 1,800 researchers at 120 institutes to advance impactful breast cancer research.
Professor Anderiesz believes it is essential for all members of the breast cancer community to consistently seek opportunities to raise awareness about the disease’s impact. This awareness should extend beyond October and include efforts to inform primary care physicians and specialists. Additionally, there is a need to promote groundbreaking research and advocate for changes in policy and care to improve outcomes for individuals affected by breast cancer.
-
Orthopaedic surgeon driven to understand & manage infection
In tandem with his clinical practice, Associate Professor Tetsworth is deeply engaged in orthopaedic research, with a keen interest in infection management, infection control, limb salvage, bone defect reconstruction, biomarker development for infection, bone growth hormone delivery, and the use of 3D printed models for reconstructing segmental bone defects.
-
State of Private Hospitals sector in Australia
During Mr Roff’s working career at APHA he has represented the private hospitals sector to nine different Federal Health Ministers and eight Prime Ministers. He believes the government should take steps to regulate the health insurance industry to protect consumers and ensure that Australians have access to affordable and comprehensive healthcare services.
-
Cardiovascular Disease Risk Guidance and Calculator get long overdue update
Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.
